Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts

Non-small cell lung cancer (NSCLC) is commonly diagnosed at advanced stages limiting treatment options. Although, targeted therapy has become integral part of NSCLC treatment therapies often fail to improve patient’s prognosis. Based on previously published criteria for selecting drug combinations f...

Descripción completa

Detalles Bibliográficos
Autores principales: Gürgen, Dennis, Conrad, Theresia, Becker, Michael, Sebens, Susanne, Röcken, Christoph, Hoffmann, Jens, Langhammer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763947/
https://www.ncbi.nlm.nih.gov/pubmed/35039644
http://dx.doi.org/10.1038/s42003-022-03016-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763947/
https://www.ncbi.nlm.nih.gov/pubmed/35039644
http://dx.doi.org/10.1038/s42003-022-03016-5

Ejemplares similares